Morning Overview on MSN
The millisecond breakthrough that could revolutionize cancer treatment
Radiation therapy treats roughly two-thirds of all cancer patients, yet healthy tissue has always absorbed collateral damage ...
Uveal melanoma is a rare cancer with limited treatment options, and approximately 90% of patients who develop metastatic disease have liver involvement. In a small randomized trial, 55% of patients ...
The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...
First High-Quality Study to Explore A Carnivore-Style Diet in Managing Metabolic Health, WhichAffects Millions of AmericansOver one-third of U.S. adults – or 115.2 million Americans – are prediabetic, ...
There was a consensus that more data are needed to answer this question, with discussions about what such a trial would look ...
Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...
Patients in the upfront surgery arm underwent surgery followed by up to 8 cycles of adjuvant chemotherapy, consisting of ...
Studies in a new meta-analysis show sex differences in average weight loss, but similar benefits across other sub-groups.
Clinician and patient responses for cutaneous cGVHD were associated with higher nonrelapse mortality when comparing worsening vs improved disease.
FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
Chronic lung disease is associated with a higher risk for infection in patients with ANCA-associated vasculitis during both induction and maintenance treatment.
In hormone receptor (HR)–positive, HER2-negative advanced breast cancer, starting CDK4/6 inhibitors (CDK4/6i) in the first line of therapy did not improve overall survival (OS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results